Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

249 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study.
Vermes A, Guchelaar HJ, van Kuilenburg AB, Dankert J. Vermes A, et al. Fundam Clin Pharmacol. 2002 Feb;16(1):39-47. doi: 10.1046/j.1472-8206.2002.00064.x. Fundam Clin Pharmacol. 2002. PMID: 11903511 Clinical Trial.
Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1-beta-D-arabinofuranosyl cytosine in a human T-lymphoblastic cell line.
Verschuur AC, Van Gennip AH, Leen R, Voƻte PA, Brinkman J, Van Kuilenburg AB. Verschuur AC, et al. Int J Cancer. 2002 Apr 1;98(4):616-23. doi: 10.1002/ijc.10211. Int J Cancer. 2002. PMID: 11920624
Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.
Maring JG, van Kuilenburg AB, Haasjes J, Piersma H, Groen HJ, Uges DR, Van Gennip AH, De Vries EG. Maring JG, et al. Br J Cancer. 2002 Apr 8;86(7):1028-33. doi: 10.1038/sj.bjc.6600208. Br J Cancer. 2002. PMID: 11953843 Free PMC article.
Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase.
Balzarini J, Sienaert R, Liekens S, Van Kuilenburg A, Carangio A, Esnouf R, De Clercq E, McGuigan C. Balzarini J, et al. Mol Pharmacol. 2002 May;61(5):1140-5. doi: 10.1124/mol.61.5.1140. Mol Pharmacol. 2002. PMID: 11961132
Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure.
van Kuilenburg AB, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJ, Maropoulos GD, Hein G, Kalhoff H, Kirk JM, Baaske H, Aukett A, Duley JA, Ward KP, Lindqvist Y, van Gennip AH. van Kuilenburg AB, et al. Biochem J. 2002 May 15;364(Pt 1):157-63. doi: 10.1042/bj3640157. Biochem J. 2002. PMID: 11988088 Free PMC article.
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. Van Kuilenburg AB, et al. Int J Cancer. 2002 Sep 20;101(3):253-8. doi: 10.1002/ijc.10599. Int J Cancer. 2002. PMID: 12209976
High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. Van Kuilenburg AB, et al. Pharmacogenetics. 2002 Oct;12(7):555-8. doi: 10.1097/00008571-200210000-00007. Pharmacogenetics. 2002. PMID: 12360106
Cyclopentenyl cytosine primes SK-N-BE(2)c neuroblastoma cells for cytarabine toxicity.
Bierau J, Van Gennip AH, Leen R, Helleman J, Caron HN, Van Kuilenburg AB. Bierau J, et al. Int J Cancer. 2003 Jan 20;103(3):387-92. doi: 10.1002/ijc.10858. Int J Cancer. 2003. PMID: 12471622
Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
van Kuilenburg AB, De Abreu RA, van Gennip AH. van Kuilenburg AB, et al. Ann Clin Biochem. 2003 Jan;40(Pt 1):41-5. doi: 10.1258/000456303321016150. Ann Clin Biochem. 2003. PMID: 12542909 Review.
249 results
Jump to page
Feedback